Abstract
Objective: Foreign clinical evidence for efficacy and safety of new pharmaceutical drugs was utilised in decisions for marketing approval in Japan without specific regulatory guidelines until a new internationally harmonised guidance for bridging strategy was introduced in 1998. We examined how foreign clinical studies were used in recent marketing approval decisions and also how the new guidelines affected the trends of foreign data acceptance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have